Logo for Kodiak Sciences Inc

Kodiak Sciences Investor Relations Material

Latest events

Logo for Kodiak Sciences Inc

R&D Day 2024

Kodiak Sciences
Logo for Kodiak Sciences

R&D Day 2024

23 Sep, 2024
Logo for Kodiak Sciences

Q2 2024

14 Aug, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Kodiak Sciences Inc

Access all reports
Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for the treatment of retinal diseases. The company's research and development efforts are centered on novel biologics designed to treat conditions like age-related macular degeneration and diabetic eye diseases, which are major causes of blindness in the developed world. Kodiak's product pipeline includes advanced clinical candidates such as tarcocimab tedromer (KSI-301), which is designed to inhibit vascular endothelial growth factors. Additionally, the company is exploring other candidates targeting different mechanisms involved in retinal diseases. The company is headquartered in Palo Alto, California, and its shares are listed on the NASDAQ.